Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.

about

Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases.iPSC-based drug screening for Huntington's disease.

P2860

Q38242113-1E60214B-5A95-4A6F-BA24-049ECC2B4B93 Q38597179-8D478065-4386-49D4-83B3-5D33302CA4B1

P2860

Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.

Item

http://www.wikidata.org/entity/Q38108756

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Experimental models for identi ...... egation and neurodegeneration.

@en

type

Item

label

Experimental models for identi ...... egation and neurodegeneration.

@en

prefLabel

Experimental models for identi ...... egation and neurodegeneration.

@en

P1476

Experimental models for identi ...... egation and neurodegeneration.

@en

P2093

Barbara Calamini

http://www.w3.org/2001/XMLSchema#string

Donald C Lo

http://www.w3.org/2001/XMLSchema#string

Linda S Kaltenbach

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans

Huntingtin interacting proteins are genetic modifiers of neurodegeneration

Molecular Genetics and Biomarkers of Polyglutamine Diseases

Oligonucleotide therapeutic approaches for Huntington disease

A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease

Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation

A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration

Disease-specific induced pluripotent stem cells

The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.

Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation

P2888

s13311-013-0195-4

P304

400-415

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13311-013-0195-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23700210

http://www.w3.org/2001/XMLSchema#string

P932

3701774

http://www.w3.org/2001/XMLSchema#string

Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.

about

P2860

P2860

Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932